Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Genomics BioSci & Tech. Co.,Ltd. (4195.TWO)

17.65
-0.50
(-2.75%)
At close: 2:08:14 PM GMT+8
Loading Chart for 4195.TWO
  • Previous Close 18.15
  • Open 18.15
  • Bid 17.50 x --
  • Ask 17.65 x --
  • Day's Range 16.90 - 18.15
  • 52 Week Range 14.30 - 22.70
  • Volume 177,006
  • Avg. Volume 151,658
  • Market Cap (intraday) 1.279B
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) --
  • EPS (TTM) -2.19
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Aug 8, 2023
  • 1y Target Est --

Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; reproductive health and cancer testing services; and contract development and manufacturing services. Genomics BioSci & Tech. Co.,Ltd. was founded in 2001 and is based in New Taipei City, Taiwan.

www.genomics.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4195.TWO

View More

Performance Overview: 4195.TWO

Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4195.TWO
7.83%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
18.41%

1-Year Return

4195.TWO
3.02%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
3.18%

3-Year Return

4195.TWO
6.24%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
10.39%

5-Year Return

4195.TWO
73.88%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
82.32%

Compare To: 4195.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4195.TWO

View More

Valuation Measures

Annual
As of 4/21/2025
  • Market Cap

    1.31B

  • Enterprise Value

    1.43B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.15

  • Price/Book (mrq)

    1.88

  • Enterprise Value/Revenue

    3.42

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -38.00%

  • Return on Assets (ttm)

    -5.36%

  • Return on Equity (ttm)

    -19.45%

  • Revenue (ttm)

    417.04M

  • Net Income Avi to Common (ttm)

    -158.49M

  • Diluted EPS (ttm)

    -2.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    261.42M

  • Total Debt/Equity (mrq)

    48.88%

  • Levered Free Cash Flow (ttm)

    -262.69M

Research Analysis: 4195.TWO

View More

Company Insights: 4195.TWO

Research Reports: 4195.TWO

View More

People Also Watch